Average annual compensation for US hematologists reached $446,700 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in hematology.

The FDA has approved Besremi for adults with essential thrombocythemia, extending ropeginterferon alfa-2b-njft into a second myeloproliferative neoplasm indication in the United States.

Mimrylo is the first FDA-approved polycythemia vera treatment designed to mimic hepcidin, targeting the iron availability that drives excessive red blood cell production.